title: How Long to Treat with Denosumab.
abstract: Chronic diseases typically require long-term treatment. Osteoporosis is a chronic disease in which fracture risk is high, and treatment is required to prevent fragility fractures. Denosumab is a fully human monoclonal antibody that inhibits RANK ligand, a powerful bone-resorbing cytokine. It is approved for individuals with osteoporosis who are at high risk for fracture. Clinical trial results confirm that denosumab is effective over the long term and has an excellent safety profile. In patients at high risk for osteoporotic fracture, therefore, long-term treatment with denosumab appears to present an attractive benefit profile.
authors.forename: Aline G
authors.initials: AG
authors.lastname: Costa
authors.forename: John P
authors.initials: JP
authors.lastname: Bilezikian
mesh_terms: D050071:Bone Density Conservation Agents / Q000008:administration & dosage*; D000069448:Denosumab / Q000008:administration & dosage*; D005264:Femoral Fractures / Q000139:chemically induced; D006801:Humans; D006996:Hypocalcemia / Q000139:chemically induced; D007239:Infections / Q000139:chemically induced; D007571:Jaw Diseases / Q000139:chemically induced; D010020:Osteonecrosis / Q000139:chemically induced; D010024:Osteoporosis / Q000188:drug therapy*; D058866:Osteoporotic Fractures / Q000517:prevention & control*; D053245:RANK Ligand / Q000037:antagonists & inhibitors*; D013997:Time Factors
chemical_list: D050071:Bone Density Conservation Agents; D053245:RANK Ligand; D000069448:Denosumab